EP0564539A4 - Sustained and continuous production of high titers of recombinant viral vectors and transduced target cells for use in gene therapy - Google Patents

Sustained and continuous production of high titers of recombinant viral vectors and transduced target cells for use in gene therapy

Info

Publication number
EP0564539A4
EP0564539A4 EP92902297A EP92902297A EP0564539A4 EP 0564539 A4 EP0564539 A4 EP 0564539A4 EP 92902297 A EP92902297 A EP 92902297A EP 92902297 A EP92902297 A EP 92902297A EP 0564539 A4 EP0564539 A4 EP 0564539A4
Authority
EP
European Patent Office
Prior art keywords
sustained
target cells
gene therapy
continuous production
viral vectors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP92902297A
Other versions
EP0564539A1 (en
Inventor
Kenneth W Culver
Richard A Knazek
R Michael Blaese
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cellco Inc
US Department of Commerce
Original Assignee
Cellco Inc
US Department of Commerce
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellco Inc, US Department of Commerce filed Critical Cellco Inc
Publication of EP0564539A1 publication Critical patent/EP0564539A1/en
Publication of EP0564539A4 publication Critical patent/EP0564539A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M23/00—Constructional details, e.g. recesses, hinges
    • C12M23/58—Reaction vessels connected in series or in parallel
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M25/00—Means for supporting, enclosing or fixing the microorganisms, e.g. immunocoatings
    • C12M25/10—Hollow fibers or tubes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M29/00—Means for introduction, extraction or recirculation of materials, e.g. pumps
    • C12M29/10—Perfusion
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M29/00—Means for introduction, extraction or recirculation of materials, e.g. pumps
    • C12M29/16—Hollow fibers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/14011—Deltaretrovirus, e.g. bovine leukeamia virus
    • C12N2740/14021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/14011—Deltaretrovirus, e.g. bovine leukeamia virus
    • C12N2740/14041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/14043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
EP92902297A 1990-12-13 1991-12-10 Sustained and continuous production of high titers of recombinant viral vectors and transduced target cells for use in gene therapy Withdrawn EP0564539A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62700890A 1990-12-13 1990-12-13
US627008 1990-12-13

Publications (2)

Publication Number Publication Date
EP0564539A1 EP0564539A1 (en) 1993-10-13
EP0564539A4 true EP0564539A4 (en) 1996-03-06

Family

ID=24512787

Family Applications (1)

Application Number Title Priority Date Filing Date
EP92902297A Withdrawn EP0564539A4 (en) 1990-12-13 1991-12-10 Sustained and continuous production of high titers of recombinant viral vectors and transduced target cells for use in gene therapy

Country Status (5)

Country Link
EP (1) EP0564539A4 (en)
JP (1) JPH06500927A (en)
AU (1) AU650711B2 (en)
CA (1) CA2098510A1 (en)
WO (1) WO1992010564A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6337209B1 (en) 1992-02-26 2002-01-08 Glaxo Wellcome Inc. Molecular constructs containing a carcinoembryonic antigen regulatory sequence
EP0689601B1 (en) * 1993-02-22 2006-10-04 The Rockefeller University Production of high titer helper-free retroviruses by transient transfection
US5512480A (en) * 1994-03-11 1996-04-30 Baxter International Inc. Flow-through bioreactor with grooves for cell retention
ES2141929T3 (en) * 1994-03-22 2000-04-01 Immune Response Corp Inc VERY EFFICIENT PRODUCTION AND ISOLATION OF VIRAL PARTICLES.
RU2187301C2 (en) 1995-06-27 2002-08-20 Бавариан Нордик А/С Capsule for cells producing viral particles, method of its preparing and using
US6344445B1 (en) 1995-10-19 2002-02-05 Cantab Pharmaceutical Research Limited Herpes virus vectors and their uses
ID26784A (en) * 1997-12-24 2001-02-08 Duphar Int Res MAKING CELLS TO PRODUCE RELATED TO BIOLOGY
CA2680130C (en) 2007-03-05 2016-01-12 Caridianbct, Inc. Cell expansion system and methods of use
AU2008262619A1 (en) * 2007-06-11 2008-12-18 Inhalation Sciences Sweden Ab A device for studying interaction between particles and lungs
EP2625577B1 (en) 2010-10-08 2019-06-26 Terumo BCT, Inc. Customizable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system
US9175259B2 (en) 2012-08-20 2015-11-03 Terumo Bct, Inc. Method of loading and distributing cells in a bioreactor of a cell expansion system
WO2015073913A1 (en) 2013-11-16 2015-05-21 Terumo Bct, Inc. Expanding cells in a bioreactor
EP3122866B1 (en) 2014-03-25 2019-11-20 Terumo BCT, Inc. Passive replacement of media
WO2015164808A1 (en) 2014-04-24 2015-10-29 Terumo Bct, Inc. Measuring flow rate
US20160090569A1 (en) 2014-09-26 2016-03-31 Terumo Bct, Inc. Scheduled Feed
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
JP7393945B2 (en) 2017-03-31 2023-12-07 テルモ ビーシーティー、インコーポレーテッド cell proliferation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2236004A1 (en) * 1973-07-02 1975-01-31 Monsanto Co
WO1990002171A1 (en) * 1988-08-31 1990-03-08 Cellco Advanced Bioreactors, Inc. In vitro cell culture reactor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4301249A (en) * 1980-07-23 1981-11-17 Merck & Co., Inc. High titer production of hepatitis A virus
US4861719A (en) * 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US4999298A (en) * 1988-04-27 1991-03-12 W. R. Grace & Co.-Conn. Hollow fiber bioreactor culture system and method
EP0491851A4 (en) * 1989-09-14 1993-02-17 Cellco, Inc. Method for the production of in vitro expanded lymphoid cells for use in adoptive immunotherapy
AU7312891A (en) * 1990-02-12 1991-09-03 Board Of Regents, The University Of Texas System Satellite cell proliferation in adult skeletal muscle

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2236004A1 (en) * 1973-07-02 1975-01-31 Monsanto Co
WO1990002171A1 (en) * 1988-08-31 1990-03-08 Cellco Advanced Bioreactors, Inc. In vitro cell culture reactor

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
R.A. HOCK ET AL.: "Expression of human adenosine deaminase from various strong promoters after gene transfer into human hematopoietic cell lines", BLOOD, vol. 74, no. 2, 1 August 1989 (1989-08-01), SAUNDERS, DULUTH, NEW YORK , US, pages 876 - 881 *
See also references of WO9210564A1 *

Also Published As

Publication number Publication date
JPH06500927A (en) 1994-01-27
CA2098510A1 (en) 1992-06-14
AU650711B2 (en) 1994-06-30
AU9124691A (en) 1992-07-08
EP0564539A1 (en) 1993-10-13
WO1992010564A1 (en) 1992-06-25

Similar Documents

Publication Publication Date Title
EP0564539A4 (en) Sustained and continuous production of high titers of recombinant viral vectors and transduced target cells for use in gene therapy
IL115584A0 (en) Viral vectors and their use in gene therapy
ZA949104B (en) Recombinant viruses and their use in gene therapy
ZA945012B (en) Viral vectors and their use in gene therapy
NO303831B1 (en) Isolated DNA sequence, vector, host cell, polypeptide and in vitro use of the polypeptide by a method for transfection of hematopoietic cells with exogenous DNA
AU694685B2 (en) Recombinant retroviruses delivering vector constructs to target cells
IL122120A (en) Recombinant mva virus containing a foreign gene inserted in a naturally occuring deletion within the genome
AU4032893A (en) Human papilloma virus genes and their use in gene therapy
MX9705937A (en) Method for preparing a recombinant adenovirus genome.
ZA952563B (en) Recombinant viruses their preparation and their use in gene therapy
ZA949103B (en) Recombinant viruses and their use in gene therapy
ZA909122B (en) Process for the preparation of genetic vectors for the nerve growth factor expression in eukaryotic cells
ZA941426B (en) Recombinant viruses and their use in gene therapy
ZA951731B (en) Genes and genetic elements aasociated with control of neoplastic transformation in mammalian cells
IL117466A0 (en) Recombinant viruses expressing lecithin-cholesterol acryltransferase and their use in gene therapy
IL157458A0 (en) Production of protein from recombinant cells in production medium suitable for cell viability and secretion and stabilization of said protein
AU7665396A (en) Recombinant viruses containing mobile genetic elements and methods of use in gene therapy
IL88371A0 (en) Directed integration of genes into a plant genome and recombinant dna,expression vectors and host cells used therefor
WO1999021589A3 (en) Use of vectors such as adenoviruses and/or adeno associated viruses and/or retroviruses and/or herpes simplex viruses and/or liposomes and/or plasmids as a vehicle for genetic information enabling mammal cells to produce agents for the treatment of bone pathologies
EP0452894A3 (en) Human cells for the high expression of genes inserted in episomal recombinant dna, their preparation and their use
ZA952242B (en) Recombinant viruses their preparation and their use in gene therapy
AU3611495A (en) Adenovirus-derived viral vectors having two therapeutic genes: suicide and immunopotentiating
ES8606502A1 (en) Expression of human alpha-1-antitrypsin in yeast.
ZA952244B (en) Recombinant viruses their preparation and their use in gene therapy
NZ304538A (en) Process for producing a modified recombinant protein in a host cell comprising preparing a single vector encoding both the exogenous protein and an enzyme capable of modifying the exogenous protein

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19930709

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE

A4 Supplementary search report drawn up and despatched

Effective date: 19960117

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19970701